[go: up one dir, main page]

NO20032614L - Farmasöytisk sammensetning som har forbedret absorberbarhet - Google Patents

Farmasöytisk sammensetning som har forbedret absorberbarhet

Info

Publication number
NO20032614L
NO20032614L NO20032614A NO20032614A NO20032614L NO 20032614 L NO20032614 L NO 20032614L NO 20032614 A NO20032614 A NO 20032614A NO 20032614 A NO20032614 A NO 20032614A NO 20032614 L NO20032614 L NO 20032614L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
improved absorbability
absorbability
improved
pharmaceutical
Prior art date
Application number
NO20032614A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032614D0 (no
Inventor
Eiji Nara
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20032614D0 publication Critical patent/NO20032614D0/no
Publication of NO20032614L publication Critical patent/NO20032614L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20032614A 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret absorberbarhet NO20032614L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000375608 2000-12-11
PCT/JP2001/010827 WO2002048142A1 (fr) 2000-12-11 2001-12-11 Compositions medicamenteuses presentant une meilleure absorbabilite

Publications (2)

Publication Number Publication Date
NO20032614D0 NO20032614D0 (no) 2003-06-10
NO20032614L true NO20032614L (no) 2003-08-05

Family

ID=18844596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032614A NO20032614L (no) 2000-12-11 2003-06-10 Farmasöytisk sammensetning som har forbedret absorberbarhet

Country Status (10)

Country Link
US (1) US20040053972A1 (fr)
EP (1) EP1350793A1 (fr)
KR (1) KR20040025881A (fr)
CN (1) CN1487936A (fr)
AU (1) AU2002221115A1 (fr)
CA (1) CA2431322A1 (fr)
HU (1) HUP0400683A2 (fr)
NO (1) NO20032614L (fr)
PL (1) PL362172A1 (fr)
WO (1) WO2002048142A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984653B2 (en) 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
UA83252C2 (uk) * 2003-09-19 2008-06-25 Астразенека Аб Похідні хіназоліну, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі, проміжна сполука
PT1671635E (pt) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Composição de antibiótico amorfo contendo cefditoreno pivoxil
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
JP4639745B2 (ja) * 2004-01-19 2011-02-23 青葉化成株式会社 難固結性のタンパク質変性抑制剤粉末およびその使用方法
US20080138437A1 (en) * 2004-02-09 2008-06-12 Shuji Sakuma Antitumor Agent
CN101933923A (zh) * 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
WO2006087919A1 (fr) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited Composition finement divisee contenant un substance peu hydrosoluble
EP1872798B1 (fr) * 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Agent anti-tumeur absorbable par l intestin
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
MX2010012442A (es) * 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
US7749300B2 (en) * 2008-06-05 2010-07-06 Xerox Corporation Photochemical synthesis of bimetallic core-shell nanoparticles
AU2009296734B2 (en) 2008-09-25 2016-02-18 Cephalon Llc Liquid formulations of bendamustine
WO2010083276A1 (fr) * 2009-01-15 2010-07-22 Cephalon, Inc. Nouvelles formes de base libre de bendamustine
PL2765990T3 (pl) * 2011-10-14 2018-01-31 Array Biopharma Inc Dyspersja stała

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees
US6211215B1 (en) * 1996-07-19 2001-04-03 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
CA2431322A1 (fr) 2002-06-20
NO20032614D0 (no) 2003-06-10
AU2002221115A1 (en) 2002-06-24
WO2002048142A1 (fr) 2002-06-20
EP1350793A1 (fr) 2003-10-08
KR20040025881A (ko) 2004-03-26
HUP0400683A2 (hu) 2004-06-28
PL362172A1 (en) 2004-10-18
CN1487936A (zh) 2004-04-07
US20040053972A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
DK1524266T3 (da) Farmaceutisk sammensætning
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
NO20025450L (no) Ny farmasöytisk sammensetning
FI20011478A0 (fi) Farmaseuttinen koostumus
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
ITTO20010005A1 (it) Formulazione farmaceutica.
ITMI20001450A0 (it) Nuova composizione farmaceutica
NO20015175L (no) Farmasöytisk sammensetning
NO20032613D0 (no) Farmasöytisk sammensetning som har en forbedret vannopplöselighet
MXPA03001425A (es) Compuestos farmaceuticos.
NO20032614L (no) Farmasöytisk sammensetning som har forbedret absorberbarhet
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
FI20022128A7 (fi) Farmaseuttinen koostumus
NO20031095L (no) Farmasoytiske sammensetninger
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
FI4488U1 (fi) Farmaseuttinen koostumus
DE10291905D2 (de) Pharmazeutische Zusammensetzung
MXPA03001857A (es) Composicones medicinales.
DK1313481T3 (da) Farmaceutisk sammensætning, som omfatter kondenserede indolforbindelser
DE10107261B4 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application